Lainscak Mitja, von Haehling Stephan, Springer Jochen, Anker Stefan D
Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Heart Fail Monit. 2007;5(3):77-82.
Cardiac biomarkers play an important role in and provide better pathophysiological understanding of chronic heart failure (CHF). Natriuretic peptides, especially B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), were found to be useful in the diagnostic assessment and prognostic stratification of patients with CHF. However, they fail to fulfill all the criteria of an ideal biomarker. Currently, we still do not have a single biomarker or a combination of biomarkers to answer all the clinically relevant questions in CHF. Consequently, some widely available biomarkers might have been overlooked in the field of heart failure. This review discusses several biomarkers, and speculates on the possible roles of combining two or more of them. In this respect, hemoglobin, cholesterol, uric acid, and recently identified proteins may prove to be relevant to the field of CHF. Lastly, we anticipate the potential of biomarkers in a variety of chronic diseases with similar pathophysiology.
心脏生物标志物在慢性心力衰竭（CHF）中发挥着重要作用，并能提供对其更好的病理生理学理解。利钠肽，尤其是B型利钠肽（BNP）和N末端前脑钠肽原（NT-proBNP），被发现对CHF患者的诊断评估和预后分层有用。然而，它们未能满足理想生物标志物的所有标准。目前，我们仍然没有单一的生物标志物或生物标志物组合来回答CHF中所有临床相关问题。因此，一些广泛可用的生物标志物在心力衰竭领域可能被忽视了。本综述讨论了几种生物标志物，并推测了将其中两种或更多种组合的可能作用。在这方面，血红蛋白、胆固醇、尿酸以及最近发现的蛋白质可能被证明与CHF领域相关。最后，我们预期生物标志物在具有相似病理生理学的多种慢性疾病中的潜力。
